MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1017/s1092852926101199

Медицинская библиотека · CNS spectrums · 2026

Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort (n = 695).

Hackshaw Kevin V, Osuna-Diaz Michelle M, Sebastian Katherine R, Nuguri Shreya Madhav, Castellvi Silvia deLamo, Yu Lianbo, Giusti M Monica, Mikulik Zhanna, Rodriguez-Saona Luis

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVE

To determine whether pharmacologic exposure is associated with differences in fibromyalgia neurobehavioral phenotypes and whether medication burden explains symptom variability within phenotypes.

METHODS

We analyzed a multisite cohort of 695 adults meeting fibromyalgia criteria, stratified into low- and high-impact phenotypes using a disability-based classification. Medication burden was quantified as total, centrally acting, and noncentrally acting medication counts. Between-phenotype differences and within-phenotype associations between medication burden and symptom severity were evaluated using nonparametric tests, Spearman correlation analyses, and multivariable linear regression models. Phenotypes were interpreted within the framework of centrally mediated neurobehavioral dysfunction.

RESULTS

Participants classified within the high-impact neurobehavioral phenotype (n = 175) demonstrated substantially greater symptom burden across fibromyalgia impact, central sensitization, depressive symptoms, pain severity, and vitality compared with low-impact participants (n = 520). Centrally acting medication burden increased stepwise with phenotype severity, whereas noncentrally acting medication use did not differ between phenotypes. Within phenotypes, centrally acting medication burden showed weak and nonsignificant associations with symptom severity after adjustment for demographic covariates, explaining minimal variance in fibromyalgia impact (R2 < 0.05).

CONCLUSIONS

Fibromyalgia symptom phenotypes remained distinct across varying levels of pharmacologic exposure, and medication burden explained little within-phenotype symptom variability. Medication burden primarily reflects downstream clinical response to symptom severity rather than a determinant of phenotype organization. These findings support the use of stable multidimensional phenotypes for mechanistic, neurobiological, and stratified intervention studies in chronic pain and related central nervous system disorders.

Для цитирования: Hackshaw Kevin V, Osuna-Diaz Michelle M, Sebastian Katherine R, Nuguri Shreya Madhav, Castellvi Silvia deLamo, Yu Lianbo, Giusti M Monica, Mikulik Zhanna, Rodriguez-Saona Luis. Fibromyalgia neurobehavioral phenotypes remain distinct across varying levels of pharmacologic exposure: evidence from a multisite cohort (n = 695).. CNS spectrums. 2026. DOI: 10.1017/s1092852926101199.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.